{
    "nct_id": "NCT03153319",
    "official_title": "Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI",
    "inclusion_criteria": "* Male or female ≥5 years of age;\n* Diagnosis of MPS I, II or VI;\n* Treatment with ERT for ≥1 year or no treatment with ERT for ≥1 year;\n* Weight ≥15 kg;\n* Significant bodily pain reported by the CHQ-PF50 or SF-36 (> 1 SD more severe [below] than the general population mean);\n* ≥ 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.\nHealthy volunteers allowed\nMust have minimum age of 5 Years",
    "exclusion_criteria": "* History of HCT less than 2 years prior to enrollment;\n* Immune suppression therapy less than 1 year prior to enrollment;\n* Active graft versus host disease;\n* Current diagnosis or history of lymphoma or other malignancy;\n* Current active infection;\n* History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);\n* Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB\n* Congestive heart failure defined by an ejection fracture <50% measured by ECHO;\n* Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome);\n* Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);\n* Hepatitis B infection (active or chronic carrier);\n* Latex sensitivity;\n* Pregnancy or breastfeeding;\n* Known or suspected allergy to adalimumab or related products;\n* Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;\n* Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or\n* Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.",
    "miscellaneous_criteria": ""
}